Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $234,160 | $5,989 | $6,083 | $10,131 |
| Short-Term Investments | $9,950 | $12,886 | $12,821 | $8,837 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $209 | $309 | $390 | $474 |
| Total Curr. Assets | $244,319 | $19,184 | $19,294 | $19,442 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $4 | $5 | $6 |
| Total NC Assets | $3 | $4 | $5 | $6 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $244,322 | $19,188 | $19,299 | $19,448 |
| Liabilities | – | – | – | – |
| Payables | $168 | $74 | $111 | $80 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $22,106 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $398 | $367 | $382 | $331 |
| Total Curr. Liab. | $22,672 | $441 | $493 | $411 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $22,672 | $441 | $493 | $411 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,345 | $1,343 | $1,343 | $1,343 |
| Retained Earnings | -$347,447 | -$548,817 | -$548,577 | -$548,298 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $567,752 | $566,221 | $566,040 | $565,992 |
| Total Equity | $221,650 | $18,747 | $18,806 | $19,037 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $244,322 | $19,188 | $19,299 | $19,448 |
| Net Debt | -$234,160 | -$5,989 | -$6,083 | -$10,131 |